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• Tipapkinogen sovacivec completely resolves CIN 3 lesions signiﬁcantly more frequently than placebo.
• Tipapkinogen sovacivec completely clears HPV16 viral DNA associated with CIN 2/3 signiﬁcantly more often than placebo.
• Tipapkinogen sovacivec has signiﬁcantly greater complete resolution rates of CIN 2/3 regardless of HR HPV type.
• Tipapkinogen sovacivec offers 36% complete resolution or partial response of CIN2/3 associated with all HR HPV types.⁎ Corresponding author at: University of Michigan, 101
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Available online 4 April 2019Background.While prophylactic human papillomavirus (HPV) vaccination exists, women are still developing
cervical intraepithelial neoplasia (CIN) grade 2 or 3 for which an immunotherapeutic, non-surgical, approach
may be effective. The primary aim was to assess the efﬁcacy of tipapkinogen sovacivec (TS) vaccine in achieving
histologic resolution of CIN2/3 associated with high risk (HR) HPV types.
Methods.Women 18 years and olderwhohad conﬁrmedCIN2/3were enrolled in a randomized, double blind,
placebo-controlled phase II trial and assigned to drug in a 2:1 ratio (vaccine:placebo). The primary endpoint oc-
curred at month 6 when the excisional therapy was performed; cytology and HR HPV typing were performed at
months 3, 6 and every sixmonths throughmonth 30. The safety population included all patients who received at
least one dose of study drug.
Results. Of the 129 women randomized to vaccine and 63 to placebo, complete resolution was signiﬁcantly
higher in the vaccine group than placebo for CIN 2/3 regardless of the 13 HR HPV types assayed (24% vs. 10%, p
b 0.05); as well as for only CIN 3 also regardless of HR HPV type (21% vs. 0%, p b 0.01). Irrespective of baseline
HPV infection, viral DNA clearance was higher in the vaccine group compared to placebo (p b 0.01). The vaccineKeywords:
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522 D.M. Harper et al. / Gynecologic Oncology 153 (2019) 521–529was well tolerated with the most common adverse events being injection site reactions.
Conclusions. The TS vaccine provides histologic clearance of CIN 2/3 irrespective ofHRHPV type in one third of
subjects and is generally safe through 30 months.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Immunotherapeutic advances against human papillomavirus (HPV)
are the next frontier in treating at least six different cancers or cancer
precursors of the cervix, anus, vulva, vagina, penis, and oropharynx
[6]. Of these, cervical cancer comprises over 80% of the HPV associated
cancer global burden [3,5], and, despite the high surgical cure rate, is
the focus of therapeutic vaccine development. While prophylactic HPV
vaccines prevent infections from half of the HR HPV types associated
with cancer, there is a clinical need for non-surgical, non-ablative ther-
apeutics to control HPV diseases. In addition, surgical and ablative ther-
apies, while effective, are associated with reproductive morbidities
[17–19]; and recurrence can occur, especially with positive surgical
margins, likely because of persistent viral infection [2,22]. Furthermore,
current screening strategies have no therapeutic option forwomenwith
persistent HPV infections whose likelihood of cancer progression is un-
known [24].
The modiﬁed vaccinia virus Ankara (MVA) is a highly attenuated
replication-deﬁcient strain of vaccinia virus used widely as a gene-
delivery system of vaccines. TS has inserted genes that code for three
proteins: human cytokine IL-2, and modiﬁed forms of HPV 16 E6 and
E7 proteins that have been rendered non oncogenic. MVA by itself con-
tributes to the immune reaction by the induction of an Interferon-alpha
response [11]. Upon sub-cutaneous injection, TS infects the surrounding
cells. The expressed HPV16 E6 and E7 proteins are then processed and
presented by dendritic cells which are co-activated by the viral infec-
tion. These dendritic cellsmigrate to the draining lymph-node and pres-
ent E6 and E7 peptides to the naive T-cells present in the lymph-node,
which should allow development of a targeted cell mediated immune
response.
Preclinical and early clinical studies suggest that TS can cause CIN2/3
resolution by induction of a cellmediated immune response [4]. Thepri-
mary aim of this study was to assess the efﬁcacy of TS compared to pla-
cebo to achieve complete histologic resolution (no CIN) at month 6 in
subjects with CIN2/3 associated with HPV 16 monoinfection. This anal-
ysis is extended to include complete resolution and partial lesion re-
sponse associated with other HR HPV infections. The secondary aims
are to assess viral DNA clearance over 2.5 years after deﬁnitive excision
at month 6 and safety assessment.
2. Methods
2.1. Study design and participants
This study was a multicenter, prospective, randomized, double-
blind, 2-arm parallel group, placebo-controlled, phase IIb trial con-
ducted in the United States, Spain, Belgium, France, and Finland,
among 66 study locations. This trial was registered at Clinicaltrials.gov
identiﬁer NCT01022346; EudraCT 2008–006946-24. The protocol was
approved by the institutional review board or ethics committee at
each participating institution, and all patients gave written informed
consent.Womenwere recruited based on known colposcopic biopsy re-
sults at their home institutions.
Women aged 18 years and older were invited to enroll if they had a
histologically conﬁrmed central pathology review (CPR) panel reconﬁr-
mation of a ﬁrst diagnosis of CIN2/3 associated with single or multiple
HR HPV infections. To be included in the study, women had to have re-
sidual disease present after biopsy, involving at least one, but no morethan two quadrants, and did not have colposcopic characteristics that
would be concerning for invasive disease. These restrictions were
enforced to rule out potential occult microinvasive cancers [25].
Women who had received a prophylactic HPV vaccine were ex-
cluded. Women who had prior excisional or ablative therapy for any
CIN, vulvar intraepithelial neoplasia (VIN) or vaginal intraepithelial
neoplasia (VaIN), or any atypical endometrial or glandular cells or carci-
noma were excluded. In addition, women were excluded if they were
pregnant or breast-feeding, co-infected with hepatitis B, hepatitis C, cy-
tomegalovirus, Epstein Barr virus or HIV, or had other immune deﬁcient
states.
2.2. Study randomization, dosing and blinding
Study subjects were randomized in a 2:1 ratio (TS vaccine:placebo)
and stratiﬁed based on the HR HPV type: HPV 16 monoinfection (stra-
tum 1) vs. other HR HPV single or multiple infections (stratum 2),
which are deﬁned as the alpha 5, 6, 7 and 9 clades (HPV 51; and HPV
56; and HPV 18, 39, 45, 59, 68; and HPV 16, 31,33, 35, 52, 58, respec-
tively as detailed in Table 1). Placebo doses were prepared and labelled
in identical syringes by a study pharmacist at each institution.
The study CPR was blinded to the randomization process, as were
the laboratory personnel performing HPV typing and clinical personnel
delivering the injections.
2.3. Procedures
Study subjects with CIN2/3 were recruited from August 2009–
September 2011. Those meeting study eligibility were assigned to
drug or placebo which was injected subcutaneously in the thigh, on
days 1, 8, and 15.
Subjects returned at month 3 andmonth 6 for cytology and HR HPV
testing. Colposcopy was performed at month 3 where biopsies were
taken only at the investigator's discretion. At month 6, subjects
underwent deﬁnitive treatment (loop electrosurgical excision proce-
dure (LEEP/LLETZ) or conization) as well as HR HPV typing. Subjects
continued follow-up every sixmonths untilmonth 30with repeat cytol-
ogy, HRHPV testing, adverse event assessments and colposcopy and bi-
opsy, if clinically needed.
Subjects recorded injection site reactions in their diary every day for
seven days following each injection, to assess tenderness, pruritus, ery-
thema, induration and pain. Adverse events were recorded using the
Medical Dictionary of Regulatory Activities (MedDRA) version 16.1
throughout the trial. Serious adverse eventswere recorded and assessed
by both the site investigators and the blinded medical monitor. These
data, including hematology and blood chemistries, were reviewed for
safety in real time.
2.4. Outcomes
Theprimary efﬁcacy endpointwas the individual histological resolu-
tion at six months after the ﬁrst injection in the HPV16 monoinfected
modiﬁed intent to treat (mITT) population deﬁned as subjects receiving
at least one dose of study drug andwhowere conﬁrmed to have CIN2 or
3 at baseline by the CPR panel. Other exploratory efﬁcacy endpoints in-
cluded histological complete resolution or partial response (CIN1) six
months after the ﬁrst injection. These exploratory analyses included
age, CIN category, HPV type infection, and number of quadrants of lesion
Table 1
Demographics of study patients at baseline by randomization group: Intent to Treat (ITT)
population for safety analysis.
Tipapkinogen
sovacivec
vaccine
Placebo
N= 136 N= 70
Age, yrs. mean (SD) 30.1 (7.8) 29.8
(7.6)
Range (Min–max), yrs 18–60 19–50
≤30 years, n (%) 84 (62) 44 (63)
N30 years, n (%) 52 (38) 26 (37)
Ethnicity/Race, n (%)
Hispanic 32 (24) 9 (13)
Not Hispanic, Black 10 (7) 8 (11)
Not Hispanic, White 89 (65) 51 (73)
Not Hispanic, Other 5 (4) 2 (3)
Global, n (%)
US 84 (62) 40 (57)
Western Europe 52 (38) 30 (43)
Central panel review histologic diagnoses, n
(%)
bCIN 2a 5 (4) 6 (9)
CIN 2 53 (39) 30 (43)
CIN 3 76 (56) 33 (47)
Adenocarcinoma-in-situa 1 (1) 1 (1)
Body mass index (BMI) (kg/m2) mean (SD) 25.2 (5.9) 25.2
(6.8)
History of small pox vaccine, n (%)
Yes 9 (7) 6 (9)
No 92 (68) 41 (59)
Unknown 35 (26) 23 (33)
Stratum 1 – HPV 16 mono-infections 56 (41) 29 (41)
Stratum 2b 80 (59) 41 (57)
Single genotype 27 (34) 12 (29)
Multiple genotypes 53 (66) 29 (71)
a Omitted from ITT population to create modiﬁed ITT (mITT) population for analysis.
b Stratum 2 could be one of 7 different combinations:
1. HPV 16 AND one or more of 31, 33, 35, 52, 58.
2. One or more of 31, 33, 35, 52, 58.
3. One or more of 18, 39, 45, 59, 68.
4. HPV 16 AND 18, 39, 45, 59, 51, 56, 68 AND one or more of 31, 33, 35, 52, 58.
5. One or more of HPV 18, 39, 45, 59, 51, 56, 68 AND one or more of 31, 33, 35, 52, 58.
6. HPV 16 AND one or more of 31, 33, 35, 51, 52, 56, 58, 66, 73, 82.
7. Other combinations of single or multiple genotypes not listed above.
523D.M. Harper et al. / Gynecologic Oncology 153 (2019) 521–529at baseline, as well as race/ethnicity, and number of biopsies. Secondary
endpoints included viral DNA clearance of baseline HPV over 2.5 years,
as well as long term safety.
2.5. Statistical analyses
The population for safety analysis comprised all women who re-
ceived either vaccine or placebo injections regardless of study comple-
tion. The analysis of efﬁcacy for the study did not have a predeﬁned
per-protocol population. The main analysis population was a modiﬁed
intent to treat (mITT) population deﬁned as only patients who are con-
ﬁrmed to have CIN 2/3 at baseline by the CPR panel andwho completed
at least the six -onth follow-up surgical excision.
The sample size was not determined by a formal power calculation
but is based on a feasibility assessment of possible patient recruitment
and the likely distribution of HPV types. An interim administrative
look (IAL) was performed on the month 6 consensus histology diagno-
ses and was based on a Bayesian assessment of the predictive probabil-
ity of success in a phase III trial given the interim results. The pre-
deﬁned analysis plan was developed for completion regardless of the
IAL decision.
We explored the following null and alternative hypotheses: the
treatment resolution rate is b60% or the treatment resolution rate is
less than double the control resolution rate, compared to whether the
treatment resolution rate is at least 60% and the treatment resolution
rate is at least double the control resolution rate. The 60% resolutionrate was considered the lowest clinically acceptable rate given that sur-
gical cures range from 75 to 100% [2].
Descriptive analyses corresponded to a priori and post hoc stratiﬁca-
tion variables: by age (N30 years old vs ≤ 30 years old), and by baseline
diagnosis (CIN2 vs CIN3) and by HPV infection types (HPV 16
monoinfection, HPV16 infection with any of the other 12 HR HPV
types, non-HPV16 HR infections and all 13 HR HPV types). Statistical
signiﬁcance was reported at the p b 0.05 and p b 0.01 levels for chi-
square and Fisher's exact test.
Univariate andmultivariate logistic regressionwere used to evaluate
a priori and post hoc impact of the treatment with and without adjust-
ment on age, HPV16 status, HPV type, CIN grade, ethnicity/race, number
of biopsies and number of quadrants of disease at baseline. Wald 95%
conﬁdence intervals are reported for individual rates and odds ratios
with signiﬁcance at p b 0.05.
Viral DNA clearance time was presented using Kaplan-Meier curves
where unstratiﬁed log-rank tests were used to compare treatment
groups by a priori and post hoc stratiﬁcation. All calculations were per-
formed with SAS 9.4 [23] with signiﬁcance at p b 0.05.
3. Results
700 patients were screened with 206 meeting study eligibility
(Fig. 1) between August 2009 and September 2013 (last patient last
visit). The intent to treat (ITT) safety population included 136 study
subjects who received TS vaccine and 70 who received placebo; 56 sub-
jects were in Stratum 1 (HPV 16 monoinfection) and received vaccine
and 29 received placebo. Stratum 2 enrolled 80 to vaccine and 41 to pla-
cebo. Table 1 shows equitable distributions between treatment groups
for age, race, body mass index (BMI), CIN2/3 distribution and strata al-
location in this population.
The modiﬁed intent to treat (mITT) population received at least one
dose of vaccine and had a conﬁrmed entry biopsy of CIN 2 or 3 by CPR
panel, resulting in 129 subjects receiving vaccine vs. 63 receiving pla-
cebo. In the HPV16 monoinfection stratum, 55 were randomized to
the vaccine and 27 to placebo; in stratum 2, 74were randomized to vac-
cine and 36 to placebo.
3.1. Primary aim (Table 2)
Histologic complete resolution from CIN 2/3 at month 6, among the
HPV 16 monoinfected women occurred in 18% (95% CI: 8–28%) of the
vaccine group compared to 4% (95% CI: 0–11%) of the placebo group,
resulting in a vaccine efﬁcacy of 80% (95% CI: 67–88%).
Other exploratory histologic endpoints at month 6 for women in-
fected with at least HPV 16 and any other HR HPV type showed com-
plete resolution from CIN 2/3 in 18% (95% CI: 4–32%) of the vaccine
group vs. 8% (95% CI:−7–24%) of the placebo group, with a vaccine ef-
ﬁcacy of 53% (95% CI: 47–61%). Complete resolution of womenwith CIN
2/3 who were infected with any number of HPV infections that are any
HR HPV type except HPV 16 occurred in 35% (95% CI: 21–49%) of the
vaccine group and 17% (95%CI: 2–32%) of the placebo group,with a vac-
cine efﬁcacy of 52% (95% CI: 38–66%). Within this HPV infected group
complete resolution of CIN 3 alone occurred signiﬁcantly more often
(p b 0.05) in the vaccine group (36% (95% CI: 46–57%)) than the placebo
group (0% (95% CI: -2–2%)), with a vaccine efﬁcacy of 100% (95% CI:
85–100%). When all HR HPV types were considered, complete resolu-
tion from CIN 2/3 occurred signiﬁcantly more often in the vaccine
group (24% (95% CI: 17–31%)) than the placebo group (10% (95% CI:
2–17%)) (p b 0.05), with a vaccine efﬁcacy of 60% (95% CI: 54–67%).
For the subset of womenwith any HRHPV type and a CIN 3 baseline le-
sion, complete resolution occurred signiﬁcantly more often in the vac-
cine group (21% (95% CI: 12–30%)) than the placebo group (0% (95%
CI: −2–2%)) (p b 0.01), with a vaccine efﬁcacy of 100% (95% CI:
95–100%). The complete resolution rate never exceeded the a priori
60% threshold, but the vaccine induced resolution rates exceeded
Safety Populaon - Randomly Dosed 2:1 (N=206)
Randomized to Tipapkinogen sovacivec (n=136)
Received 3 injecons (n=129)
Received 2 injecons (n=4)
Received 1 injecon (n=3)
Randomized to Placebo (n=70)
Received 3 injecons (n=69)
Received 2 injecons (n=1)
Received 1 injecon (n=0)
Paent withdrawal through month 6 (n=15)
2 due to adverse events
1 violaon of entry criteria
1 protocol violaon
4 withdrew consent/refused treatment
3 failed to return for visits
4 other
Paent withdrawal through month 6 (n=9)
1 death - overdose of psychotropic drugs
1 violaon of entry criteria
1 protocol violaon
3 withdrew consent/refused treatment
2 failed to return for visits
1 other
Stratum 1 HPV 16 mono-infecon (n=56)
Stratum 2* (n=80)
Stratum 1 HPV 16 mono-infecon (n=29)
Stratum 2* (n=41)
Randomized to Placebo (n=63)
Stratum 1 HPV 16 mono-infecon (n=55)
Stratum 2* (n=74)
Stratum 1 HPV 16 mono-infecon (n=27)
Stratum 2* (n=36)
Randomized to Tipapkinogen sovacivec (n=129)
Modiﬁed Intent to Treat at month 6 (N=192)
Received at least one dose
Had a central panel review of entry biopsy conﬁrmed as CIN 2 or CIN 3
Fig. 1. Trial schematic—700 Patients Screened and subsequent enrollment in the safety population and the modiﬁed intent to treat (mITT) population.
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subgroups: the stratum 1 HPV16 monoinfection for both the CIN 2/3
and CIN 3 populations as well as the non-HPV 16 infections and all HR
HPV infections for the CIN 3 population (Supplemental Figure S1).
Histologic partial response at month six was never signiﬁcantly dif-
ferent between vaccine and placebo groups for any HR HPV stratum.
When combining the histologic complete resolution and partial re-
sponse rates together, the women with CIN 3 associated with any HR
HPV type had a signiﬁcantly higher resolution/response rate of 32% in
the vaccinated group vs. 12% in the placebo group (p b 0.01); in addi-
tion, women with CIN 2/3 associated with any HR HPV type had a 36%
resolution/response rate vs. 21% in the placebo group (p b 0.05).
3.2. Logistic regression predictions
3.2.1. Univariate
Three univariate models were explored (Table 3). The ﬁrst two
models explored complete resolution vs. no response in two populations:
a) among both CIN 2 and 3 baseline lesions, b) among only CIN 3 baselinelesions. In theﬁrstmodel, regardless of treatment, HPV16 infectionswere
signiﬁcantly less likely to resolve than any other HRHPV type (OR=0.42
(95% CI: 0.20–0.88)); and those with three biopsies at baseline were sig-
niﬁcantlymore likely to resolve compared to thosewith a single diagnos-
tic biopsy (OR = 3.17 (95% CI: 1.03–9.75)). Among only CIN 3 women,
those of Hispanic ethnicity/race were signiﬁcantly more likely to
completely resolve their lesion vs. non-Hispanic white women (OR =
10.64 (95% CI: 3.00–37.73)); and women with three biopsies at baseline
were also signiﬁcantly more likely to have lesion resolution compared
to a single biopsy (OR = 5.36 (95% CI: 1.14–25.26)).
The third univariate model explored the combination of complete
resolution and response vs. no response for the CIN 2/3 baseline. In
this model, only ethnicity/race showed signiﬁcance in resolution/re-
sponse at month six.
3.2.2. Multivariate
There were three corresponding multivariate models adjusting for
all single univariate factors. The ﬁrst multivariate model showed that
vaccine treatment signiﬁcantly increased the odds of complete
Table 2
Six-month primary endpoints of complete resolution and partial response, mITT population.
Tipapkinogen Sovacivec Placebo
Complete
resolution
Partial
response
No
response
Complete
resolution
Partial
response
No
response
Vaccine efﬁcacya for complete
resolution
% (95% CI)
HPV 16 mono infection
10/55
(18.2%)
7/55
(12.7%)
38/55
(69.1%)
1/27
(3.7%)
5/27
(18.5%)
21/27
(77.8%)
80%
(67–88%)
Age: ≤30 yrs
6/32
(18.8%)
4/32
(12.5%)
22/32
(68.8%)
0/14
(0.0%)
2/14
(14.3%)
12/14
(85.7%)
Age: N30 yrs
4/23
(17.4%)
3/23
(13.0%)
16/23
(69.6%)
1/13
(7.7%)
3/13
(23.1%)
9/13
(69.2%)
CIN2
4/16
(25.0%)
1/16
(6.3%)
11/16
(68.8%)
1/9
(11.1%)
2/9
(22.2%)
6/9
(66.7%)
CIN3
6/39
(15.4%)
6/39
(15.4%)
27/39
(69.2%)
0/18
(0.0%)
3/18
(16.7%)
15/18
(83.3%)
100%
(91–100%)
HPV 16 infection with any other HR HPV type
5/28
(17.9%)
4/28
(14.3%)
19/28
(67.9%)
1/12
(8.3%)
0/12
(0.0%)
11/12
(91.7%)
53%
(47–61%)
Age: ≤30 yrs
3/20
(15.0%)
4/20
(20.0%)
13/20
(65.0%)
1/8
(12.5%)
0/8
(0.0%)
7/8
(87.5%)
Age: N30 yrs
2/8
(25.0%)
0/8
(0.0%)
6/8
(75.0%)
0/4
(0.0%)
0/4
(0.0%)
4/4
(100.0%)
CIN2
3/13
(23.1%)
3/13
(23.1%)
7/13
(53.8%)
1/8
(12.5%)
0/8
(0.0%)
7/8
(87.5%)
CIN3
2/15
(13.3%)
1/15
(6.7%)
12/15
(80.0%)
0/4
(0.0%)
0/4
(0.0%)
4/4
(100.0%)
100%
(80–100%)
Non-HPV 16 infections of any HR HPV type and
number of types
16/46
(34.8%)
4/46
(8.7%)
26/46
(56.5%)
4/24
(16.7%)
2/24
(8.3%)
18/24
(75.0%)
52%
(38–66%)
Age: ≤30 yrs
8/27
(29.6%)
3/27
(11.1%)
16/27
(59.3%)
3/16
(18.8%)
1/16
(6.3%)
12/16
(75.0%)
Age: N30 yrs
8/19
(42.1%)
1/19
(5.3%)
10/19
(52.6%)
1/8
(12.5%)
1/8
(12.5%)
6/8
(75.0%)
CIN2
8/24
(33.3%)
3/24
(12.5%)
13/24
(54.2%)
4/13
(30.8%)
1/13
(7.7%)
8/13
(61.5%)
CIN3⁎
8/22
(36.4%)
1/22
(4.5%)
13/22
(59.1%)
0/11
(0.0%)
1/11
(9.1%)
10/11
(90.9%)
100%
(85–100%)
All HR HPVb types⁎
31/129
(24.0%)
15/129
(11.6%)
83/129
(64.3%)
6/63
(9.5%)
7/63
(11.1%)
50/63
(79.4%)
60%
(54–67%)
Age: ≤30 yrs
17/79
(21.5%)
11/79
(13.9%)
51/79
(64.6%)
4/38
(10.5%)
3/38
(7.9%)
31/38
(81.6%)
Age: N30 yrs
14/50
(28.0%)
4/50
(8.0%)
32/50
(64.0%)
2/25
(8.0%)
4/25
(16.0%)
19/25
(76.0%)
CIN2
15/53
(28.3%)
7/53
(13.2%)
31/53
(58.5%)
6/30
(20.0%)
3/30
(10.0%)
21/30
(70.0%)
CIN3⁎⁎
16/76
(21.1%)
8/76
(10.5%)
52/76
(68.4%)
0/33
(0.0%)
4/33
(12.1%)
29/33
(87.9%)
100%
(95–100%)
a Vaccine efﬁcacy is calculated as the ratio of the difference between the rates of complete resolution of the lesion at month 6 with placebo from the rate from treatment with
tipapkinogen sovacivec divided by the rate with complete resolution at month 6 treated with tipapkinogen sovacivec. [(Rate complete resolution(tip sov)− Rate complete resolution (pla-
cebo)) / (Rate complete resolution (tip sov))].
b All HRHPV means regardless of high risk human papillomavirus type of the 13 types for which we tested.
⁎ p b 0.05 in comparison to respective placebo.
⁎⁎ p b 0.01.
525D.M. Harper et al. / Gynecologic Oncology 153 (2019) 521–529resolution among the CIN 2/3 baseline population (aOR= 4.68 (95% CI:
1.57–13.98)), and Hispanic women were signiﬁcantly more likely to
completely resolve their CIN 2/3 lesion at month six than non-
Hispanic white women (aOR = 3.11 (95% CI: 1.21–8.02)).
The secondmultivariatemodel considered all factors in prediction of
CIN 3 resolution. Because there were zero complete resolutions in the
placebo group, an adjusted model for vaccine effects was not possible.
Signiﬁcant racial differences were seen in complete resolution.
The third multivariate model was similar to the ﬁrst in that the vac-
cine treatment signiﬁcantly increased odds of complete resolution or
partial response at month six among the CIN 2/3 baseline population
(aOR = 2.82 (95% CI: 1.26–6.30)), but only non-Hispanic Black
women remained signiﬁcantly more likely that non-Hispanic White
women to resolve/respond (aOR = 5.91 (95% CI: 1.78–19.55)). Of
note, in all multivariate models the type of HPV infection did not signif-
icantly predict month six resolution or response.
3.2.3. 2.5 year follow-up
While all women were to be followed to study end, few subjects
needed to be histologically evaluated during this time frame (Table 4).Of those who had complete resolution at month 6, 24% (4/17) in the
TS arm had worse histology detected at 2.5 years. Likewise, one of two
(50%) placebo subjects had worse histology at longer term follow-up.
Of those who had partial response at month 6, 12% (3/25) in the TS
armhadworse histology detected at followup;while oneof three (33%)
placebo subjects had worse histology at follow-up.
This long-term follow-up study resulted in amean follow-up time of
822 days for the treatment group and 756 days for the placebo group
with 76% of the treatment group and 66% of the placebo group staying
in the study for N811 days.
3.3. Secondary aim
Viral DNA clearance of all CIN 2/3 regardless of HRHPV type (Fig. 2A)
was signiﬁcantly greater in the vaccine treated cohort than in placebo
cohort (p b 0.01); in addition, Fig. 2B shows that viral DNA clearance
among the women with baseline CIN 3, regardless of HR HPV type,
was signiﬁcantly superior with vaccine than placebo (p ≤ 0.01). For spe-
ciﬁc HR HPV types (Fig. 2C), the vaccine was superior to placebo for the
following subgroups: 1) the stratum 1 cohort of HPV 16 monoinfected
Table 3
Predictors of histologic resolution/response.
Among CIN 2/3
Predicting complete resolution vs.
no response
Among CIN 3
Predicting complete resolution vs.
no response
Among CIN 2/3
Predicting complete resolution and
partial response vs. no response
OR (95% CI) aOR (95% CI) OR (95% CI) aOR (95% CI) OR (95% CI) aOR (95% CI)
All HR HPV types
Vaccine 3.11
1.21–7.98
4.68
1.57–13.98
NE NE 2.13
1.05–4.33
2.82
1.26–6.30
Placebo Referent Referent Referent Referent Referent Referent
HPV 16
Vaccine 4.21
0.91–19.59
2.09
0.81–5.34
Placebo Referent Referent Referent
HPV infection type
HPV 16 0.42
0.20–0.88
0.42
0.18–1.01
0.40
0.13–1.18
0.37
0.09–1.57
0.63
0.33–1.18
0.68
0.33–1.39
Non HPV 16 Referent Referent Referent Referent Referent Referent
Age 1.02
0.97–1.07
1.05
0.99–1.11
1.03
0.96–1.10
1.02
0.93–1.12
1.02
0.98–1.06
1.04
1.00–1.09
CIN grade
CIN 2 Referent Referent Referent Referent
CIN 3 0.49
0.23–1.02
0.33
0.14–0.80
0.58
0.31–1.08
0.46
0.23–0.93
Ethnicity/race
White Referent Referent Referent Referent Referent Referent
Black 3.07
0.82–11.51
4.42
0.99–19.79
6.50
0.95–44.59
5.10
0.61–42.77
4.10
1.41–11.88
5.91
1.78–19.55
Hispanic 3.49
1.49–8.19
3.11
1.21–8.02
10.64
3.00–37.73
6.22
1.47–26.23
2.55
1.18–5.50
2.07
0.91–4.71
Other 1.34
0.14–12.67
1.18
0.11–12.50
1.59
0.28–9.11
1.40
0.22–8.82
Number of biopsies
One biopsy Referent Referent Referent Referent Referent Referent
Two biopsies 1.60
0.67–3.83
2.82
0.94–8.49
1.25
0.34–4.66
1.43
0.26–7.91
1.34
0.66–2.69
2.00
0.87–4.60
Three biopsies 3.17
1.03–9.75
3.75
0.93–15.10
5.36
1.14–25.26
3.41
0.44–26.57
2.10
0.79–5.60
2.51
0.79–7.90
Four biopsies 1.85
0.17–19.85
1.56
0.09–25.67
1.96
0.30–12.75
3.36
0.39–28.95
Number of quadrants of disease
One quadrant Referent Referent Referent Referent Referent Referent
Two quadrants 0.55
0.24–1.25
0.31
0.11–0.91
0.86
0.25–2.98
1.07
0.16–6.99
0.53
0.26–1.07
0.38
0.16–0.87
NE means not evaluable.
526 D.M. Harper et al. / Gynecologic Oncology 153 (2019) 521–529women, 2) the cohort with any HR HPV infection except HPV 16, and
3) the cohort of HPV16 co-infected with any other HR HPV infection.
3.4. Safety
In general, the TS vaccine was well tolerated but with nearly all re-
cipients having an injection site reaction, 29% being graded as severe ac-
cording to the FDA Guidance for Industry: Toxicity Grading Scale for
Healthy Adult and Adolescent Volunteers Enrolled in Preventative Vac-
cine Clinical Trials and Common Terminology Criteria for Adverse
Events v3.0, for which two patients discontinued the study (Supple-
mental Table S1). Of the patients who received placebo, 37% experi-
enced injection site reactions graded as mild, moderate, or severe. All
other adverse events or pregnancy outcomes were evenly distributed
between the treatment groups. One death occurred in the placebo arm
of the study (due to medication overdose) approximately six months
after the last study injection; the death was considered unrelated to
the study drug. One subject reported severe lymphadenopathy after
the ﬁrst two injections, delaying the third TS injection. One subject in
the placebo arm reported invasive lobular breast carcinoma detected
prior to month 3.
There were six cancers and three adenocarcinoma-in-situ diagnoses
detected between the time of the trial injections (vaccine/placebo) and
the six-month excision. All three adenocarcinoma-in-situ were in the
placebo arm. Three squamous cell cancers were detected in the vaccine
arm, and three cancers (one each: adenosquamous, adeno, andsquamous) were detected in the placebo arm. Risk factor analyses of
these cancers are discussed in the supplement.
4. Discussion
Our study is the largest study to date following women for the lon-
gest time frame trialing a therapeutic vaccine for HPV associated CIN
2/3. The TS vaccine was signiﬁcantly associated with greater complete
resolution rates of histologic CIN 3 disease as well as with signiﬁcantly
greater viral DNA resolution regardless of HR HPV type. The vaccine
was expected to act in the HPV 16 alpha 9 clade as determined in
phase 1 studies by T cell proliferation, anti-MVA antibodies and anti-
E6/E7 neutralizing antibodies [4], but this work shows that all HR HPV
types responded to some degree to the vaccine. This presents the hy-
pothesis that CIN 3, the most severe dysplasia, with greater expression
of E6/E7 proteins are susceptible to the neutralizing antibodies signiﬁ-
cantly more than the CIN 2 lesions, and that this immunotherapy
might be combinedwith other checkpoint inhibitors formore advanced
stages of HPV associated cancers that are expressing E6/E7 proteins.
We showed signiﬁcant complete resolution of CIN 2/3 from all HR
HPV types at 24% in the vaccine group, similar to a pilot report by Alvarez
showing a 26% complete resolution of HPV 16 CIN 2/3 lesions after parti-
cle mediated epidermal delivery, intramuscular delivery or intralesional
delivery of a DNA based therapeutic HPV 16 E7-calreticulin based com-
pound [1]; and similar to a phase 1 trial ofHPV16E6adjuvantedwith can-
dida (Pepcan) that resulted in 17%–20% complete resolution at higher
Table 4
Histologic follow up through month 30 in mITT population.
Tipapkinogen
Sovacivec
Placebo
N= 129 N= 63
Histological assessments
available post month 6
57/129 (44%) 24/63 (38%)
Histological assessments
available post month 6 for
those subjects who had
complete resolution at month
6
17/31 (22%) 2/6 (33%)
Subjects with complete
resolution at month 6 who
had worse histology at 2.5
years
4/17 (24%) 1/2 (50%)
Histology at 2.5 years 1 subject: CIN
1
1 subject: CIN
2
2 subjects:
CIN 3
1 subject: adenocarcinoma in
situ
Histological assessment
available post month 6 for
those subjects who had partial
response at month 6
25/46 (54%) 3/13 (23%)
Subjects with a partial response
at month 6 who had worse
histology at 2.5 years
3/25 (12%) 1/3 (33%)
Histology at 2.5 years 1 subject: CIN
2
2 subjects:
CIN 3
1 subject: intracervical
carcinoma with stromal
invasion, squamous cell
carcinoma
527D.M. Harper et al. / Gynecologic Oncology 153 (2019) 521–529doses [15]. Two small phase 2 trials with a heat shock fusion protein
(SGN-00101) [12,21] and a compound similar to TS (TG4001) did not
reach complete resolution [28]. In addition, the placebo complete resolu-
tion rate (10%) and partial response (11%) at month 6 for all HR HPV
types were similar to other immunotherapeutic studies for CIN2/3 [20].
The absolute complete resolution rate did not meet the a priori pri-
mary objective, in our study, of 60%, which was identiﬁed as a clinically
acceptable resolution threshold, but the therapeutic vaccine did meet
the resolution rate above twice the placebo resolution rate for HPV 16
monoinfected CIN 2/3 and for all HR HPV CIN 3 lesions. Given the ther-
apeutic harms of surgical excision [17–19]with reproductivemorbidity,
an argument can be made that a lower therapeutic resolution/response
could be both clinically and cost effective from a broader perspective
than just cancer prevention.
The combination complete resolution/partial response rates in our
study (36%) are similar to the 40% regression rate documented for
VGX-3100 against CIN2/3 associated with HPV 16/18 in a phase 2b
trial [28]; to that seen by Pepcan in a phase 1 trial [15]; and to the 48%
partial resolution seen in the phase 2 TG4001 trial [12].
We cannot know from this study if a higher resolution rate could
have been seen if the endpoint had been evaluated later than month
6. For instance, another immunotherapeutic agent, VGX-3100, showed
a marginally higher efﬁcacy for CIN2/3 associated with HPV 16/18 re-
gression to normal at month 9, but likewise did not meet the 60% reso-
lution threshold [28]. In addition, we did not test whether a booster
vaccination at month 3 could have increased month 6 resolution rates;
nor did we test whether fewer than three doses could accomplish the
same current resolution or response.
Of those with resolution or response post-surgical treatment only a
small proportion of subjects had worsening pathology at 2.5 years
follow-up most likely due to incomplete excision of the original lesion.
Of the 2.9% of enrolled subjects diagnosedwith a malignancy, it is likely
that these were prevalent cancersmissed at diagnosis, supported by the
literature which shows an incident rate of 2.0–4.1% due to the limita-
tions of colposcopy-guided biopsies [7,14].Viral DNA clearance is a secondary indicator of efﬁcacy. Prior work
indicates that women who have viral DNA clearance of their type spe-
ciﬁc persistent HPV infection are more likely to maintain resolution of
their CIN2/3 [26]. In addition, women with surgical excisions resulting
in positive endocervical margins have more than two-fold the recur-
rence rates of CIN 2/3 because of residual viral infection [8]. Unlike the
VGX-3100 study [28], viral DNA clearance in our study was measured
and analyzed separately from histologic resolution/response. Our vac-
cine was signiﬁcantly superior to placebo in complete viral DNA clear-
ance for both CIN 2/3 and CIN 3 for all HR HPV types considered,
although it did not provide complete clearance in all subjects. Complete
viral DNA clearance was sustained over the 2.5 year follow-up in both
vaccine and placebo groups.
This study has several strengths. A simple subcutaneous injection is
an easy implementation strategy. Even with less resolution/response
than anticipated, this vaccine could offer a preliminary reduction in sur-
gical excisions avoiding their resulting reproductivemorbidity harms. In
addition, this study had a rigorous adjudicating CPR to review all histo-
logic specimens reducing the misdiagnosis at study entry. The precise
HPV detection methodology allowed both HPV 16 monoinfection and
other HR HPV types to be detected from all sample aliquots. The rigor-
ous study design protected subjects by detecting the prevalent cancers
without impacting trial results. Finally, most of the study participants
were followed for a 30-month time frame, the longest duration of
follow-up in a therapeutic vaccine trial to date.
The study also has limitations. The study was not powered for a spe-
ciﬁc efﬁcacy; and the baseline viral load could not differentiate incident
from persistent infections. Another limitation was the six-month time
frame for immunotherapeutic response which, in hindsight, may have
been too short. Finally, balancing the potential harm of CIN 3
progressing to cancerwith the need to understand the efﬁcacy of an im-
munotherapeutic agent is challenging even over a short time frame, as
the colposcopic impression is maximally sensitive for CIN3+ disease
at only 70% [13].
Immunologic therapeutic HPV vaccines offer a potential non-
surgical option forwomenwith cervical pre-cancerswhichmight be ex-
tended to other HPV associated precursors or cancers in the future. The
spectrum of decreasing incidence and mortality from HPV associated
cancers includes prophylactic vaccination [16], skin barriers such as
condoms [10], continued education about sexuality [27], creating po-
tentially hormonally hostile environments [9], with the largest success
to date being the opportunistic and organized screening programs sim-
pliﬁedmost recently by the approval of primary HRHPV screening tests
at ﬁve-year intervals [29]. The treatment of cervical pre-cancerous le-
sions may eventually include ﬁrst round therapeutic vaccination
which we have also shown to be safe through 30 months prior to
going to excisional surgery if necessary.
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